SHIJIAZHUANG CITY, China–(BUSINESS WIRE)–Lianhua Qingwen Capsules, an innovative patent traditional Chinese medicine, is produced by China�s Yiling Pharmaceutical under the guidance of TCM Collateral Disease Theory. It has been widely used for symptoms caused by mild and moderate COVID-19, such as fever, cough and fatigue, been recommended by Diagnosis and Treatment Protocol for COVID-19 (Trial Version 4-8), published jointly by Chinas National Health Commission and National Administration of TCM. On November 23, Lianhua Qingwen was launched in the Philippines and many Philippine consumers have rushed to purchase this medicine.
Is there any notice for taking Lianhua Qingwen Capsules? How to take it to realize the maximal efficacy? Correct way is to take it orally, 3 capsules 1 time, 3 times a day. Keep taking it regularly can treat influenza caused by toxic heat attacking lung with symptoms of fever, aversion to cold, muscular soreness, nasal obstruction & running nose, cough, headache, dry & sore throat, reddish tongue, yellow tongue coating or oily tongue coating, etc.
While using Lianhua Qingwen, please stop smoking, drinking, and dont eat spicy, raw, cold and oily foods. Patients with hypertension or heart disease should use with caution, patients with chronic disease such as diabetes, liver disease, kidney disease should take medicine under doctors direction. Children, pregnant women, nursing mother, senile and infirm patients or those with week spleen should take it under doctors direction. Also interaction may appear if administered accompanied with other medicine, consult with doctors or pharmacists for details.
The registration number of Lianhua Qingwen Capsules in the Philippines is THPR-50 and the product category is traditional herbal drugs. Now this medicine is available in Mercury Drug, Southstar Drug and Watson.
Contacts
First Name: Li
Last Name: Kristy
E-mail:kristyli@chuhaimedia.com.cn
Phone No.: +86 85962566
QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…
SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…
DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…
Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…
EAST BRUNSWICK, N.J. & BENGALURU, India--(BUSINESS WIRE)--$WIPRO #AIprinciples--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO),…
THOMASVILLE, Ga.--(BUSINESS WIRE)--Cleaver-Brooks announces that it has been acquired by Miura Co., Ltd., a leading…